Takara Bio Inc.

Takara Shuzo Co., Inc.

Other

National Center of Neurology and Psychiatry

Nippon Medical School Foundation

Tatsuji Enoki

Ikunoshin Kato

Hiroaki Sagawa

Nobuto Koyama

Katsushige Ikai

Junichi Mineno

Eiji Nishiyama

Toshikazu Nishie

Eiji Kobayashi

Takanari Tominaga

Hiromu Ohnogi

Hua-Kang Wu

Fuyuko Takashima

Nobuko Muraki

Takahiro Marui

Takeshi Sakai

Jun Tomono

Mitsuko Ideno

Michio Hagiya

Yasuhiro Kawano

Hikaru Takakura

Fu-Gong Yu

Sachiko Okamoto

Tomomi Otsuji

Katsumi Sugiyama

Shuhei Sakamoto

Akiko Kato

Kinuko Nagamine

Takashi Okada

Kiyozo Asada

Takashi Uemori

Hiroyuki Mukai

Yoshimi Sato

Hideto Chono

Junko Yamamoto

Kaoru Kojima

Kazue Miyake

Akihiro Kondo

Katsuyuki Dodo

Masanari Kitagawa

Hirofumi Yoshioka

Osamu Takeda

Kazuyori Ochiai

Hiromi Kinoh

Suzu Deguchi

Tuo-Ping Li

Hitoshi Sakakibara

Shuohao Huang

Haruhisa Sawaragi

Yuka Hirase

Asako Hatsuyama

Yoshinori Tanaka

Mariko Moriyama

Motoko Ueda

Masayuki Kishimoto

Risa Kato

Haruo Oyashiki

Kinuko Ogawa

Naoko Ashida

Masae Sato

Meiko Jin

Mie Yabuuchi

Fumiko Iwamoto

Hironori Okada

Yoko Yamaguchi

Yasuhiro Tosaka

Yuki Yamamoto

The present invention provides a nucleic acid which encodes an adeno-associated virus (AAV) capsid protein mutant that contains a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62 or a peptide comprising an amino acid sequence produced by substituting, deleting, inserting and/or adding one or several amino acid residues in an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62; DNA comprising the nucleic acid; a cell harboring the DNA; and a method for producing the cell.

AAV mutant having brain-targeting property

In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.

Lymphocyte production method

Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.

Fibronectin fragment to be used for stem cell production

The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.

Method for producing endothelial cells

The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Mutant of adeno-associated virus (AAV) capsid protein

Provided is a method for producing non-enveloped viral particles, comprising a step for obtaining a fraction containing non-enveloped viral particles by removing precipitates which are produced in a step for adding a substance which reduces the solubility of proteins under acidic conditions and/or a substance which precipitates under acidic conditions to a neutral or basic sample containing non-enveloped viral particles, and acidifying the sample after the addition of the substance.

Method for producing non-enveloped viral particles

The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.

Method for manufacturing non-enveloped virus

Provided are a production method for non-enveloped virus particles which is characterized in that a sample including non-envelopes virus particles is treated with PEG in at least two concentrations; a kit used in said production method; non-enveloped virus particles produced using said production method; and a pharmaceutical composition having the non-envelopes virus particles as an active ingredient.

Production method for non-enveloped virus particles

The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell.

AAV variant

According to the present invention, an AAV vector having a higher titer compared with those of conventional ones can be produced using a cell into which a nucleic acid capable of expressing miRNA is introduced artificially. An AAV vector produced using the cell and a composition containing the viral vector as an active ingredient are very useful as gene transfer means in the studies or clinical practice of gene therapies.

Cell capable of producing adeno-associated virus vector

The present invention relates to a method for production of a cell population containing a pluripotent stem cell, said method comprising a step of treating a somatic cell which has been contacted with nuclear reprogramming factors under nutrient-starved condition, and/or a step of treating the somatic cell with an agent capable of arresting cell cycle. The present invention allows induction and growth of pluripotent stem cells at high frequency, and it also allows production of pluripotent stem cells with high efficiency. The nuclear reprogramming factors to be used may be any selected from the group consisting of OCT4, SOX2, c-MYC, KLF4, NANOG and LIN28.

Method for production of pluripotent stem cell

A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.

Process for production of natural killer cells

The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.

Process for producing cytotoxic lymphocytes

A method for transferring a gene into a fat cell or progenitor fat cell comprising the step of infecting the fat cell or progenitor cell with a retrovirus vector having a foreign gene in the presence of a substance having both of a retrovirus-binding site and a target cell-binding site in the molecule or a mixture of a substance having a retrovirus-binding site and a substance having a target cell-binding site, the target cell-binding site having a region that can bind to VLA-5 and/or a region that can bind to VLA-4.

Method for transfer of gene into fat cell or progenitor fat cell

A method for preparing lymphocytes characterized in that the method comprises the step of carrying out expansion in the presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand.

Method of producing lymphocytes

Growing community of inventors

Kyotanabe, Japan

Tatsuji Enoki